Market Overview:
The global cluster headache syndrome drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of cluster headache syndrome, rising awareness about the condition, and technological advancements in the field of cluster headache syndrome drugs. However, factors such as high cost of treatment and lack of awareness about cluster headache syndrome in some regions are likely to restrain the growth of this market during the forecast period. The global Cluster Headache Syndrome Drug Market is segmented on the basis of type, application, and region. On the basis of type, triptans are expected to account for a major share in this market duringthe forecast period owingto their high efficacyin treatingcluster headaches.
Product Definition:
Cluster headache syndrome is a rare disorder characterized by recurrent, short-lived episodes of intense pain in one or more clusters of the head. These headaches are accompanied by other symptoms, such as nasal congestion and red eyes. Cluster headache syndrome drug is used to prevent or reduce the frequency of cluster headaches.
Triptans:
Triptans are medications that are used to reduce pain caused by migraine. They work by decreasing the amount of serotonin in the brain, which reduces pain. Serotonin is a chemical messenger that helps regulate pain and other body functions. The most commonly used triptans are sumatriptan (Imitrex), rizatriptan (Maxalt), and zolmitriptan (Zomacton).
Octreotide :
Octreotide is a type of artificial growth hormone. It is used to treat patients suffering from chronic head pain due to an abnormal increase in the size (volume) of the brain. Octreotide acts by reducing or eliminating the pain caused by increased intracranial pressure (ICP).
Application Insights:
The application segment is sub-divided into abortive, transitional and preventive. The abortive category includes Category 1 drugs which are first line treatments for HCFS. These include sumatriptan, rizatriptan, zolmitriptan and naratriptan. Category 2 drugs which are second line treatment for cluster headache but should be used in combination with Category 1 drugs as a first line of treatment include ergots triptans (buspirone being the most prominent) and opioid analgesics (being the most prominent). Preventative category includesCategory 3 through 6 agents that show potential to become future billion dollar industries; these preventative medications have not been approved by regulatory authorities yet due to high costs or other concerns such as side effects or drug interactions etc., preventing them from gaining approval from regulatory authorities.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to favorable reimbursement policies, increasing prevalence of cluster headache and rising awareness about diagnosis and treatment options. In addition, presence of key players with extensive research & development capabilities is also likely to contribute toward growth in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to rapid economic development coupled with improving healthcare infrastructure in emerging countries such as China and India. Furthermore, growing medical tourism industry will further boost demand for these drugs in this region during the forecast period (2018-2030).
Europe accounted for a significant share of revenue generation owing to high prevalence of CFS across European countries such as Norway, Spain, Italy etc.
Growth Factors:
- Increasing prevalence of cluster headache syndrome (CHS)
- Growing awareness about CHS among people
- Rising demand for better treatment options for CHS patients
- Availability of government funding for research on CHS drugs
- Technological advancements in the field of drug development
Scope Of The Report
Report Attributes
Report Details
Report Title
Cluster Headache Syndrome Drug Market Research Report
By Type
Triptans, Octreotide , Opioids, Others
By Application
Abortive, Transitional, Preventativ
By Companies
Center Laboratories Inc, Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd, TrioxBio Inc, GSK, AstraZeneca, Pfizer, Sun Pharmaceutical, Aurobindo, Par Pharmaceutical, Wockhardt, Fresenius Kabi, Sagent Pharmaceuticals, Chengdu Tiantaishan Pharmaceutical, Sinopharm A-Think Pharmaceuticals, Sihuan Pharmaceutical Holdings Group, Shanghai Soho-Yiming Pharmaceuticals, Yibin Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Cluster Headache Syndrome Drug Market Report Segments:
The global Cluster Headache Syndrome Drug market is segmented on the basis of:
Types
Triptans, Octreotide , Opioids, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Abortive, Transitional, Preventativ
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Center Laboratories Inc
- Eli Lilly and Company
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- TrioxBio Inc
- GSK
- AstraZeneca
- Pfizer
- Sun Pharmaceutical
- Aurobindo
- Par Pharmaceutical
- Wockhardt
- Fresenius Kabi
- Sagent Pharmaceuticals
- Chengdu Tiantaishan Pharmaceutical
- Sinopharm A-Think Pharmaceuticals
- Sihuan Pharmaceutical Holdings Group
- Shanghai Soho-Yiming Pharmaceuticals
- Yibin Pharmaceutical
Highlights of The Cluster Headache Syndrome Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Triptans
- OctreotideÂ
- Opioids
- Others
- By Application:
- Abortive
- Transitional
- Preventativ
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cluster Headache Syndrome Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cluster headache syndrome (CHS) is a rare condition that causes severe headaches. The headaches are usually concentrated in one area on the head and can be so severe that they interfere with daily life. CHS is caused by a problem with the nerves that control blood flow to the brain. This can lead to inflammation and swelling in the tissues around the brain, which in turn causes pain. Some people who have CHS also have problems with their vision or hearing. Treatment for CHS typically includes medication and/or surgery to reduce pressure on the brain or relieve symptoms.
Some of the key players operating in the cluster headache syndrome drug market are Center Laboratories Inc, Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd, TrioxBio Inc, GSK, AstraZeneca, Pfizer, Sun Pharmaceutical, Aurobindo, Par Pharmaceutical, Wockhardt, Fresenius Kabi, Sagent Pharmaceuticals, Chengdu Tiantaishan Pharmaceutical, Sinopharm A-Think Pharmaceuticals, Sihuan Pharmaceutical Holdings Group, Shanghai Soho-Yiming Pharmaceuticals, Yibin Pharmaceutical.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cluster Headache Syndrome Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cluster Headache Syndrome Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cluster Headache Syndrome Drug Market - Supply Chain
4.5. Global Cluster Headache Syndrome Drug Market Forecast
4.5.1. Cluster Headache Syndrome Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cluster Headache Syndrome Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Cluster Headache Syndrome Drug Market Absolute $ Opportunity
5. Global Cluster Headache Syndrome Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Cluster Headache Syndrome Drug Market Size and Volume Forecast by Type
5.3.1. Triptans
5.3.2. Octreotide
5.3.3. Opioids
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Cluster Headache Syndrome Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Cluster Headache Syndrome Drug Market Size and Volume Forecast by Application
6.3.1. Abortive
6.3.2. Transitional
6.3.3. Preventativ
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Cluster Headache Syndrome Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Cluster Headache Syndrome Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Cluster Headache Syndrome Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cluster Headache Syndrome Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cluster Headache Syndrome Drug Demand Share Forecast, 2019-2029
9. North America Cluster Headache Syndrome Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cluster Headache Syndrome Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cluster Headache Syndrome Drug Market Size and Volume Forecast by Application
9.4.1. Abortive
9.4.2. Transitional
9.4.3. Preventativ
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Cluster Headache Syndrome Drug Market Size and Volume Forecast by Type
9.7.1. Triptans
9.7.2. Octreotide
9.7.3. Opioids
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Cluster Headache Syndrome Drug Demand Share Forecast, 2019-2029
10. Latin America Cluster Headache Syndrome Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cluster Headache Syndrome Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cluster Headache Syndrome Drug Market Size and Volume Forecast by Application
10.4.1. Abortive
10.4.2. Transitional
10.4.3. Preventativ
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Cluster Headache Syndrome Drug Market Size and Volume Forecast by Type
10.7.1. Triptans
10.7.2. Octreotide
10.7.3. Opioids
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Cluster Headache Syndrome Drug Demand Share Forecast, 2019-2029
11. Europe Cluster Headache Syndrome Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cluster Headache Syndrome Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cluster Headache Syndrome Drug Market Size and Volume Forecast by Application
11.4.1. Abortive
11.4.2. Transitional
11.4.3. Preventativ
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Cluster Headache Syndrome Drug Market Size and Volume Forecast by Type
11.7.1. Triptans
11.7.2. Octreotide
11.7.3. Opioids
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Cluster Headache Syndrome Drug Demand Share, 2019-2029
12. Asia Pacific Cluster Headache Syndrome Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cluster Headache Syndrome Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cluster Headache Syndrome Drug Market Size and Volume Forecast by Application
12.4.1. Abortive
12.4.2. Transitional
12.4.3. Preventativ
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Cluster Headache Syndrome Drug Market Size and Volume Forecast by Type
12.7.1. Triptans
12.7.2. Octreotide
12.7.3. Opioids
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Cluster Headache Syndrome Drug Demand Share, 2019-2029
13. Middle East & Africa Cluster Headache Syndrome Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Cluster Headache Syndrome Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cluster Headache Syndrome Drug Market Size and Volume Forecast by Application
13.4.1. Abortive
13.4.2. Transitional
13.4.3. Preventativ
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Cluster Headache Syndrome Drug Market Size and Volume Forecast by Type
13.7.1. Triptans
13.7.2. Octreotide
13.7.3. Opioids
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Cluster Headache Syndrome Drug Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Cluster Headache Syndrome Drug Market: Market Share Analysis
14.2. Cluster Headache Syndrome Drug Distributors and Customers
14.3. Cluster Headache Syndrome Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Center Laboratories Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly and Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis AG
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Teva Pharmaceutical Industries Ltd
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. TrioxBio Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GSK
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AstraZeneca
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pfizer
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Sun Pharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Aurobindo
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Par Pharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Wockhardt
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Fresenius Kabi
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Sagent Pharmaceuticals
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Chengdu Tiantaishan Pharmaceutical
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Sinopharm A-Think Pharmaceuticals
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Sihuan Pharmaceutical Holdings Group
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Shanghai Soho-Yiming Pharmaceuticals
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Yibin Pharmaceutical
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
